Compositions and methods for treatment of nervous system disorders

• US 20050096311A1
• Filed: 10/30/2003
• Published: 05/05/2005
• Est. Priority Date: 10/30/2003
• Status: Abandoned Application

• Current Assignee: Cns Response
• Original Assignee: Cns Response
• Inventors: Brandt, Leonard, Emory, W. Hamlin, Suffin, Stephen C.
• Application Number:
  US10/697,497
• Publication Number:
  US 20050096311A1
• Time in Patent Office: Days
• US Class Current: 514/217
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/045 Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system

Abstract

The present invention contemplates compositions and methods to treat patients having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Also described is a method to predict the probability of a significant recovery when a treating an individual patient having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Specifically, methods for predicting patient prognosis include, but are not limited to, quantitative electroencephalography, psychometric test batteries, biological indicators, brain metabolic indicators, genotype profiles, neuroimaging, objective test measurements and multi-modalities. The present invention also discloses a device providing an organized dispensation of the above formulations such that the patient or medical personnel may easily and accurately decrease the daily dosage of a third drug and increase the daily dosage of a formulation comprising an anticonvulsant and a neuroactive modulator.

Claims

1. A formulation comprising oxcarbazepine and an antidepressant, wherein said antidepressant is selected from the group consisting of bupropion, bupropion derivatives and bupropion metabolites.

2. The formulation of claim 1, further comprising a third drug selected from the group consisting of selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, antipsychotic drugs, antianxiety/anxiolytic drugs, barbituates, stimulants, antiparkinsonian drugs, analgesic drugs, cardiac agents and nutriceuticals.

3. The formulation of claim 1, wherein the form of said formulation is selected from the group consisting of a tablet, capsule, oral liquid, intrapulmonary liquid, transdermal patch, a polymer-coated tablet, a microparticle, a nanoparticle, an aerosol, fast-dissolve compound and a sterile injectable solution.

4. A method of treatment, comprising:

a) providing a patient exhibiting at least one symptom of a nervous system disorder, and

b) administering to the patient a formulation comprising oxcarbazepine and bupropion such that at least one symptom of said nervous system disorder is reduced.

5. The method of claim 4, wherein said nervous system disorder is selected from the group consisting of childhood disorders, cognitive disorders, substance disorders, schizophrenia, psychotic disorders mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, sexual disorders, gender identity disorders, eating disorders, sleep disorders, impulse-control disorders, adjustment disorders or personality disorders.

6. The formulation of claim 4, further comprising a third drug selected from the group consisting of selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, antipsychotic drugs, antianxiety/anxiolytic drugs, barbiturates, stimulants, antiparkinsonian drugs, analgesic drugs, cardiac agents and nutriceuticals.

7. The method of claim 4, wherein said formulation comprises a compounded formulation.

8. The method of claim 7, wherein said compounded formulation further comprises said third drug.

9. A method of treatment, comprising:

a) providing a patient exhibiting at least one symptom of a nervous system disorder and is being treated with a dose of a third drug, wherein said patient is non-remissive; and

b) administering to said patient a formulation comprising a dose of oxcarbazepine and a dose of bupropion such that at least one symptom of said nervous system disorder is reduced.

10. The method of claim 9, wherein said formulation further comprises said third drug.

11. The method of claim 9, further comprising step (c), decreasing said dose of said third drug.

12. The method of claim 9, wherein said admistering of step (b) is performed over a period of time such that said dose of oxcarbazepine and said bupropion is increased.

13. The method of claim 9, wherein said nervous system disorder is selected from the group comprising childhood disorders, cognitive disorders, substance disorders, schizophrenia, psychotic disorders mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, sexual disorders, gender identity disorders, eating disorders, sleep disorders, impulse-control disorders, adjustment disorders or personality disorders.

14. The method of claim 9, wherein said drug is selected from the group comprising selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, antipsychotic drugs, antianxiety/anixolytic drugs, barbiturates, stimulants, antiparkinsonian drugs, analgesic drugs, cardiac agents and nutriceuticals.

15. The method of claim 9, wherein said formulation comprises a compounded formulation.

16. The method of claim 15, wherein said compounded formulation comprises said third drug.